Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.37 CAD
Change Today +0.005 / 1.39%
Volume 212.0K
TLT On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 4:15 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

theralase technologies inc (TLT) Snapshot

Open
C$0.36
Previous Close
C$0.36
Day High
C$0.37
Day Low
C$0.35
52 Week High
12/23/14 - C$0.78
52 Week Low
05/15/14 - C$0.21
Market Cap
38.2M
Average Volume 10 Days
575.3K
EPS TTM
C$-0.05
Shares Outstanding
104.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERALASE TECHNOLOGIES INC (TLT)

Related News

No related news articles were found.

theralase technologies inc (TLT) Related Businessweek News

No Related Businessweek News Found

theralase technologies inc (TLT) Details

Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in bio-stimulative and bio-destructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical scientific research, clinical trials, and technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and development activities. The company sells its products to licensed healthcare practitioners, such as medical doctors, chiropractors, physical therapists, and athletic therapists in Canada, the United States, and internationally. Theralase Technologies Inc. is headquartered in Toronto, Canada.

theralase technologies inc (TLT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$115.0K
Compensation as of Fiscal Year 2013.

theralase technologies inc (TLT) Key Developments

Theralase Technologies Inc. Partners with CiToxLAB Safety and Health Research Laboratories to Provide Toxicology and Safety Pharmacology for the Lead Anti-Cancer Photo Dynamic Compound (PDC), TLD-1433

Theralase Technologies Inc. announced that it has partnered with CiToxLAB Safety and Health Research Laboratories (CiToxLAB) to provide toxicology and safety pharmacology for the lead anti-cancer Photo Dynamic Compound (PDC), TLD-1433. In order to further identify the safe dosing range of TLD-1433 to be used in human clinical trials for Non Muscle Invasive Bladder Cancer (NMIBC) planned for later this year, CitoxLAB will study the effects that TLD-1433 has on biological systems, alone and when light activated and analyze any interactions that these effects may have on the functioning of normal biological processes. Theralase is currently in development of a platform of anti-cancer Photo Dynamic Therapy (PDT) technologies for the destruction of numerous cancers, commencing with the destruction of NMIBC.

Theralase Technologies Inc. Announces the Confirmation of its Strategic Initiatives for 2015

Theralase Technologies Inc. announced the confirmation of its strategic initiatives for 2015. The company is now fully funded to commence and complete its two core strategic initiatives in 2015. The first core strategic initiative for the Company is the launch of the next generation TLC-2000 'Cell Sensing' therapeutic laser system in Canada in April 2015 and in the US and Europe in the third quarter 2015. This technology will revolutionize the therapeutic laser industry by providing healthcare practitioners with a technology that can sense where a patient's tissue is damaged and then deliver an exact dose of healing laser light energy to the region to heal the condition in the safest and most effective way possible. The technology is expected to generate significant revenue for Theralase over the next few years as the US pain market, estimated at $100 million in size, is expected to grow rapidly with the aging population. The second core strategic initiative is the commencement of a Phase I /II a clinical study to evaluate the safety and tolerability of Photo Dynamic Therapy (PDT) in the destruction of Non-Muscle Invasive Bladder Cancer (NMIBC) as a primary outcome measure. As a secondary outcome measure, Theralase will investigate the efficacy of its technology in the destruction of NMIBC. Various milestones leading up to this milestone include: commencement and completion of a toxicity analysis, completion of the clinical protocol, Health Canada Clinical Trial Application (CTA) meetings, Food and Drug Administration (FDA) Investigational New Drug (IND) application meetings, completion of non-Good Manufacturing Practices (GMP) and GMP manufacture of the lead Photo Dynamic Compound (PDC). Pending commercialization of this technology, Theralase is expected to significantly increase its revenues. The US bladder cancer market is estimated to cost the American medical system $4 billion annually with all cancers costing over $77 billion annually.

Theralase Technologies Inc. Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells

Theralase Technologies Inc. announced that it has identified a potential mechanism of how its lead anti-cancer drug works to destroy cancer cells and has also discovered a new application of the lead drug that may lead to the ability to detect the presence of cancer cells. Theralase's lead Photo Dynamic Compound TLD-1433, when combined with transferrin (a naturally occurring iron-binding blood plasma glycoprotein found in its body), was recently described in the provisional U.S patent application, entitled, Transferrin Enhanced Photo Dynamic Therapy Cancer Destruction. Theralase's Ruthenium based PDC TLD-1433 combined with transferrin has now been branded and trademarked by the Company, as Rutherrin. Rutherrin has demonstrated an ability to significantly increase the targeting of bladder cancer cells and in the process, significantly increase the efficacy and safety of the treatment procedure. TLD-1433 is able to bind to transferrin to form Rutherrin as evident from the change in absorption spectra in the chart below. These findings support the preferential uptake of Rutherrin (transferrin-bound TLD-1433) by cancer cells that are known to have an increased number of transferrin receptors. Rutherrin allows TLD-1433 to uptake faster and in larger quantities into rat bladder cancer cells (AY27) than without transferrin by 300%. These photos also demonstrate that Rutherin is not located in the nuclei of the cell, but localizes into the cytoplasm of the cancer cell, potentially at the mitochondria. Thus how TLD-1433 and Rutherrin work is by localization into the As an added advantage, both TLD-1433 and Rutherrin may be used as tools to detect cancer cells through fluorescence. The fluorescent signature has been even further enhanced by the introduction of transferrin. Fluorescent micrograph images of rat cancer cells (AY27) with TLD-1433 alone and when combined with transferrin to produce Rutherrin demonstrate the fluorescent signature. In 2015, Theralase will execute on two strategic objectives aimed at increasing long term shareholder value in both Therapeutic Laser Technology and Photo Dynamic Therapy divisions; specifically: the launch of next generation TLC-2000 therapeutic laser with Cell Sensing technology that provides higher efficacy than any other therapeutic laser on the market and the commencement of Health Canada /FDA Phase I /II a clinical trial in humans for Non Muscle Invasive Bladder Cancer aimed at the destruction of bladder cancer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLT:CN C$0.37 CAD +0.005

TLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLT.
View Industry Companies
 

Industry Analysis

TLT

Industry Average

Valuation TLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.1x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERALASE TECHNOLOGIES INC, please visit www.theralase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.